SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI. Hip disease and the prognosis of total hip replacements: a review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987-99. J Bone Joint Surg Br 2001; 83: 57986.
  • 2
    Havelin LI, Engesaeter LB, Espehaug B, Furnes O, Lie SA, Vollset SE. The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. Acta Orthop Scand 2000; 71: 33753.
  • 3
    Lucht U. The Danish Hip Arthroplasty Register. Acta Orthop Scand 2000; 71: 4339.
  • 4
    Puolakka TJ, Pajamaki KJ, Halonen PJ, Pulkkinen PO, Paavolainen P, Nevalainen JK. The Finnish Arthroplasty Register: report of the hip register. Acta Orthop Scand 2001; 72: 43341.
  • 5
    Robertsson O, Knutson K, Lewold S, Lidgren L. The Swedish Knee Arthroplasty Register 1975-1997: an update with special emphasis on 41,223 knees operated on in 1988-1997. Acta Orthop Scand 2001; 72: 50313.
  • 6
    Soderman P. On the validity of the results from the Swedish National Total Hip Arthroplasty register. Acta Orthop Scand Suppl 2000; 71: 133.
  • 7
    Havelin LI, Fenstad AM, Salomonsson R, Mehnert F, Furnes O, Overgaard S, et al. The Nordic Arthroplasty Register Association. Acta Orthop 2009: 19.
  • 8
    Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 1971; 14: 1357.
  • 9
    Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 115760.
  • 10
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 228793.
  • 11
    Bengtson S, Knutson K. The infected knee arthroplasty: a 6-year follow-up of 357 cases. Acta Orthop Scand 1991; 62: 30111.
  • 12
    Berbari EF, Hanssen AD, Duffy MC, Steckelberg JM, Ilstrup DM, Harmsen WS, et al. Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis 1998; 27: 124754.
  • 13
    Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 171320.
  • 14
    Fitzgerald RH Jr, Nolan DR, Ilstrup DM, van Scoy RE, Washington JA 2nd, Coventry MB. Deep wound sepsis following total hip arthroplasty. J Bone Joint Surg Am 1977; 59: 84755.
  • 15
    Jamsen E, Huhtala H, Puolakka T, Moilanen T. Risk factors for infection after knee arthroplasty: a register-based analysis of 43,149 cases. J Bone Joint Surg Am 2009; 91: 3847.
  • 16
    Poss R, Thornhill TS, Ewald FC, Thomas WH, Batte NJ, Sledge CB. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984; 182: 11726.
  • 17
    Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty: risk factors and treatment in sixty-seven cases. J Bone Joint Surg Am 1990; 72: 87883.
  • 18
    Wymenga AB, van Horn JR, Theeuwes A, Muytjens HL, Slooff TJ. Perioperative factors associated with septic arthritis after arthroplasty: prospective multicenter study of 362 knee and 2,651 hip operations. Acta Orthop Scand 1992; 63: 66571.
  • 19
    Barrack RL. Economics of the infected total knee replacement. Orthopedics 1996; 19: 7802.
  • 20
    Berbari EF, Osmon DR, Duffy MC, Harmssen RN, Mandrekar JN, Hanssen AD, et al. Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis 2006; 42: 21623.
  • 21
    Hebert CK, Williams RE, Levy RS, Barrack RL. Cost of treating an infected total knee replacement. Clin Orthop Relat Res 1996; 331: 1405.
  • 22
    Sculco TP. The economic impact of infected joint arthroplasty. Orthopedics 1995; 18: 8713.
  • 23
    Bengtson S. Prosthetic osteomyelitis with special reference to the knee: risks, treatment and costs. Ann Med 1993; 25: 5239.
  • 24
    Havelin LI. The Norwegian Joint Registry. Bull Hosp Jt Dis 1999; 58: 13947.
  • 25
    Furnes O, Espehaug B, Lie SA, Vollset SE, Engesaeter LB, Havelin LI. Early failures among 7,174 primary total knee replacements: a follow-up study from the Norwegian Arthroplasty Register 1994-2000. Acta Orthop Scand 2002; 73: 11729.
  • 26
    Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005; 23 Suppl 39: S18894.
  • 27
    Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model: New York: Springer-Verlag; 2000.
  • 28
    R: a language and environment for statistical computing. 2008. URL: http://www.R-project.org.
  • 29
    Dixon WG, Watson K, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al, for the British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 236876.
  • 30
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294300.
  • 31
    Dale H, Hallan G, Espehaug B, Havelin LI, Engesaeter LB. Increasing risk for revision due to deep infection after hip arthroplasty. Acta Orthop 2009; 80: 63945.
  • 32
    Norwegian Arthroplasty Register. Annual report of the Norwegian Arthroplasty Register 2008: department of orthopaedic surgery. Bergen (Norway): NAR; 2008.
  • 33
    Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection 2003; 31: 99108.
  • 34
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 227585.
  • 35
    Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists. Arthritis Rheum 2007; 56: 112533.
  • 36
    Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 340312.
  • 37
    Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti–tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 62834.
  • 38
    Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 175464.
  • 39
    Den Broeder AA, Creemers MC, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007; 34: 68995.
  • 40
    Pappas DA, Giles JT. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections? Curr Opin Rheumatol 2008; 20: 4506.
  • 41
    Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 164554.
  • 42
    Fehring T, Hanssen, AD, Pelligrini VD Jr, Spangehl, MJ. Infected total joint arthroplasty. In: Proceedings of the 69th Annual Meeting of the American Academy of Orthopaedic Surgeons; 2002; Dallas. 2002.
  • 43
    Ainscow DA, Denham RA. The risk of haematogenous infection in total joint replacements. J Bone Joint Surg Br 1984; 66: 5802.
  • 44
    Stinchfield FE, Bigliani LU, Neu HC, Goss TP, Foster CR. Late hematogenous infection of total joint replacement. J Bone Joint Surg Am 1980; 62: 134550.
  • 45
    Deacon JM, Pagliaro AJ, Zelicof SB, Horowitz HW. Prophylactic use of antibiotics for procedures after total joint replacement. J Bone Joint Surg Am 1996; 78: 175570.
  • 46
    Knobben BA, van Horn JR, van der Mei HC, Busscher HJ. Evaluation of measures to decrease intra-operative bacterial contamination in orthopaedic implant surgery. J Hosp Infect 2006; 62: 17480.
  • 47
    Arthursson AJ, Furnes O, Espehaug B, Havelin LI, Soreide JA. Validation of data in the Norwegian Arthroplasty Register and the Norwegian Patient Register: 5,134 primary total hip arthroplasties and revisions operated at a single hospital between 1987 and 2003. Acta Orthop 2005; 76: 8238.
  • 48
    Espehaug B, Furnes O, Havelin LI, Engesaeter LB, Vollset SE, Kindseth O. Registration completeness in the Norwegian Arthroplasty Register. Acta Orthop 2006; 77: 4956.